Journal
BLOOD REVIEWS
Volume 23, Issue 2, Pages 61-65Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2008.06.002
Keywords
Antiplatelet agents; Arterial thrombosis; Platelets; Protease-activated receptors; Thrombin
Categories
Funding
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
Arterial thrombosis, manifesting as acute myocardial infarction or ischaemic stroke, is the single most common cause of morbidity and mortality in industrialised societies. Platelets are a pre-requisite for the formation of arterial thrombi and, as a consequence, novel antiplatelet agents are sought to meet the significant clinical need for a potent, safe, and orally available therapy for the management of cardiovascular disease. Platelet thrombin receptors, termed protease-activated receptors (PARs), represent one promising candidate for the development of such therapy. This review outlines the role of platelet PARs in haemostasis and thrombosis and discusses the preclinical and clinical evidence supporting the potential of PAR antagonists as novel antiplatelet therapy. (c) 2008 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available